Status:

COMPLETED

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Lead Sponsor:

Amgen

Conditions:

Anemia

Chronic Kidney Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether once monthly (QM) dosing of darbepoetin alfa is non-inferior to that of once every 2 week (Q2W) dosing of darbepoetin alfa for the correction of anemi...

Eligibility Criteria

Inclusion

  • ≥ 18 years of age
  • Diagnosis of chronic kidney disease with eGFR of 15-59 mL/min/1.73 m2 (MDRD equation)
  • Two consecutive screening Hb values taken at least 7 days apart must each be \<10.0 g/dL
  • TSAT ≥ 15%

Exclusion

  • Upper or lower GI bleeding within 6 months before enrolment
  • ESA use within 12 weeks before enrolment
  • Uncontrolled hypertension
  • Systemic haematologic disorders
  • Prior history within 12 weeks before enrollment of events including: Acute myocardial ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis, thromboembolism.
  • Grand mal seizure within 6 months prior to enrolment
  • Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5 years prior to enrolment.
  • Red blood cell transfusion within 12 weeks prior to enrolment
  • Androgen therapy within 8 weeks prior to enrolment
  • Pregnancy or breast feeding, or inadequate contraception
  • Currently receiving immunosuppressive therapy

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

358 Patients enrolled

Trial Details

Trial ID

NCT00925587

Start Date

June 1 2009

End Date

May 1 2012

Last Update

June 4 2014

Active Locations (157)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 40 (157 locations)

1

Research Site

Gosford, New South Wales, Australia, 2250

2

Research Site

Liverpool, New South Wales, Australia, 2170

3

Research Site

New Lambton, New South Wales, Australia, 2305

4

Research Site

Randwick, New South Wales, Australia, 2031

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease | DecenTrialz